| Ytd | -3.20% | |
| 1y | -13.57% |
| Open | 1.24 | Prev Close | 1.22 | Low | 1.21 | High | 1.24 | Mkt Cap | 64.68M |
| Vol | 1.12M | Avg Vol | 296.17K | EPS | -1.41 | P/E | N/A | Forward P/E | -0.96 |
| Beta | 1.48 | Short Ratio | 5.17 | Inst. Own | 83.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 1.24 | 200-d Avg | 1.27 | 1yr Est | 5.80 |
PMVP News
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “C
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “C
PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “C
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure m
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appoi
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “
PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and PMV Pharmaceuticals (NASDAQ: PMVP - Get
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consen
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Mole
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “C
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study
PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion o
PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight t
PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst con
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “C
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: P
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock a
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst con
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as m
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a preci
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst con
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst conse
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicate
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) t
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop Fou
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharm
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst conse
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precis